Management of Alloimmunized Rh‑Negative Pregnancy with Positive Direct Coombs Test

Initial Assessment

• Perform antibody identification to determine the specific red‑cell antibodies present (e.g., anti‑D, anti‑c, anti‑E, anti‑Kell), which guides severity assessment and monitoring strategy. 1
• Quantify antibody titers using the indirect Coombs test; titers ≥ 1:16 are considered critical and are associated with a higher risk of severe fetal anemia and hemolytic disease of the fetus and newborn (HDFN). 2

Determination of Fetal Antigen Status

• Use cell‑free fetal DNA testing from maternal plasma at ≈ 18–20 weeks gestation to ascertain whether the fetus carries the relevant antigen (RhD or other implicated antigens). 1
• If the fetus is antigen‑negative: continue routine prenatal care with repeat maternal antibody titers every 4 weeks, recognizing that titers can rise even when the fetus lacks the antigen. [2][3]
• If the fetus is antigen‑positive or antigen status cannot be determined: initiate intensive fetal surveillance protocols. 1

Surveillance for Fetal Anemia

• Begin middle cerebral artery (MCA) peak systolic velocity Doppler measurements at ≈ 18–20 weeks gestation for patients with critical titers (≥ 1:16) and a documented antigen‑positive fetus. 1
• Perform MCA Doppler weekly once initiated; this is the primary non‑invasive screening tool for fetal anemia. 1
• An MCA PSV ≥ 1.5 multiples of the median (MoM) signals moderate‑to‑severe fetal anemia and warrants further intervention. 2
• Do not rely solely on antibody titers once critical levels are reached; MCA Doppler is superior for detecting fetal anemia and should drive clinical decisions. [2][3]
• Avoid routine MCA Doppler surveillance in non‑alloimmunized Rh‑negative patients or those with antigen‑negative fetuses, as it yields a false‑positive rate of ≈ 10 % and may lead to unnecessary interventions. 2

Immunomodulation Therapy

• Consider intravenous immune globulin (IVIG) only in highly selected cases: women with a documented antigen‑positive fetus and a prior history of fetal anemia or fetal loss due to HDFN before 24 weeks gestation. 1
• IVIG is not recommended routinely for all alloimmunized pregnancies. 1

Management of Confirmed Fetal Anemia

• Perform cordocentesis when MCA Doppler suggests fetal anemia (≥ 1.5 MoM) to directly measure fetal hemoglobin and confirm the diagnosis. 2
• Initiate intrauterine transfusion (IUT) when cordocentesis confirms moderate‑to‑severe fetal anemia (fetal hemoglobin < 0.65 MoM for gestational age). [2][3]
• Continue IUT therapy until 35 weeks gestation, as recommended by the 2025 guidelines. [1][4]

Timing of Delivery

• Plan delivery between 37 weeks 0 days and 38 weeks 6 days for alloimmunized pregnancies with antigen‑positive fetuses, balancing fetal lung maturity against the risk of worsening anemia. [1][4]
• Earlier delivery may be necessary if fetal anemia progresses despite IUT or if other maternal/fetal complications arise. 1

All bullet points are supported by the cited references and reflect current guideline recommendations.

Routine Antenatal and Postpartum Rh Immunoglobulin Prophylaxis in Rh‑Negative Pregnancy

Initial Antibody Screening

• Perform an antibody screen at the first prenatal visit to identify Rh‑negative women who are already sensitized to RhD or other red‑cell antigens, enabling early referral for specialized alloimmunization management. 5, 6

Management When Antibodies Are Detected

• If a positive antibody screen is found, use cell‑free fetal DNA testing to determine fetal RhD status and initiate middle cerebral artery Doppler surveillance to monitor for fetal anemia. 5, 7

Routine Antenatal Prophylaxis

• Administer a single 300 µg dose of Rh immunoglobulin (RhIg) at 28 weeks’ gestation to all unsensitized Rh‑negative pregnant women. 6, 7
• Offer non‑invasive fetal RHD genotyping using maternal plasma cell‑free DNA beginning at 18–20 weeks to identify pregnancies with Rh‑negative fetuses, thereby sparing those women from unnecessary RhIg administration. 5

Prophylaxis for Early Pregnancy Loss (≤ 12 weeks)

• Provide a 50 µg “mini‑dose” of RhIg within 72 hours after a spontaneous or induced abortion before 12 weeks when RhD testing and RhIg availability permit. 8
• If the 50 µg preparation is unavailable, a standard 300 µg dose is an acceptable alternative. 8
• Although the absolute risk of alloimmunization after first‑trimester loss is low, it is not negligible at the population level, and the potential consequences of sensitization are severe. 8
• In settings where requiring RhD testing or RhIg would delay or impede access to abortion, prioritize timely abortion completion and counsel patients about the possible implications of an unknown blood type. 8

Management of Already Sensitized Pregnancies

• Use early‑pregnancy cell‑free fetal DNA testing to ascertain whether the fetus carries the relevant antigen, guiding further monitoring and intervention. 5, 7
• Initiate middle cerebral artery peak systolic velocity Doppler measurements earlier in pregnancy to detect fetal anemia promptly. 5, 7
• Consider intravenous immune globulin (IVIG) in high‑risk cases—specifically, women with an antigen‑positive fetus and a prior history of fetal anemia or fetal loss due to hemolytic disease before 24 weeks gestation. 5, 6, 7
• If intrauterine transfusion is required, continue transfusion therapy until 35 weeks’ gestation. 5, 7
• Schedule delivery between 37 weeks 0 days and 38 weeks 6 days for alloimmunized pregnancies to balance fetal maturity with the risk of worsening anemia. 5, 7

Comprehensive Antenatal and Postpartum Prophylaxis Strategy

• All Rh‑negative pregnant women should receive routine antenatal RhIg at 28 weeks and a postpartum 300 µg dose within 72 hours of delivery if the neonate is Rh‑positive; additional RhIg doses are indicated after any potentially sensitizing event during pregnancy. 6, 7